Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

BACKGROUND:In breast cancer endocrine therapy, post-therapy Ki-67 assay of biopsy material predicts recurrence-free survival but is invasive and prone to sampling error. 18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) has shown an early agonist or 'flare' response to tamoxi...

Full description

Bibliographic Details
Main Authors:	Kurland, Brenda, Gadi, Vijayakrishna, Specht, Jennifer, Allison, Kimberly, Livingston, Robert, Rodler, Eve, Peterson, Lanell, Schubert, Erin, Chai, Xiaoyu, Mankoff, David, Linden, Hannah
Other Authors:	Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
Language:	en
Published:	BioMed Central 2012
Subjects:	FDG PET Ki-67 Breast cancer Aromatase inhibitor Trastuzumab Pharmacodynamic response Early response
Online Access:	Kurland et al. EJNMMI Research 2012, 2:34 http://www.ejnmmires.com/content/2/1/34 http://hdl.handle.net/10150/610135 http://arizona.openrepository.com/arizona/handle/10150/610135

Similar Items

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
by: Perrin E. Romine, et al.
Published: (2021-08-01)

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
by: Changjun Wang, et al.
Published: (2020-07-01)

FDG-PET-CT in the early response evaluation for primary systemic therapy of breast cancer
by: Tőkés Tímea, et al.
Published: (2014-04-01)

Malignant peripheral nerve sheath tumour of the oesophagus: a case report
by: Kento Tomizawa, et al.
Published: (2020-07-01)

Preliminary Radiogenomic Evidence for the Prediction of Metastasis and Chemotherapy Response in Pediatric Patients with Osteosarcoma Using <sup>18</sup>F-FDF PET/CT, <i>EZRIN</i> and <i>KI67</i>
by: Byung-Chul Kim, et al.
Published: (2021-05-01)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
by: Laura Díaz-Gil, et al.
Published: (2021-10-01)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2019-09-01)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2018-07-01)

Correlation Between Ki67 Expression and 18F-FDG PET/CT SUVmax in Patient with Diffuse Large B-cell Lymphoma and Their Application in Therapeutic Effect Evaluation
by: YANG Ming, et al.
Published: (2018-12-01)

Molecular Docking of Aromatase Inhibitors
by: Virapong Prachayasittikul, et al.
Published: (2011-04-01)

AROMATASE AND NEUROREGENERATION
by: Zulvikar Syambani Ulhaq
Published: (2019-01-01)

Análise das características clinicopatológicas, proliferação celular e alterações de número de cópias e metilação de genes supressores de tumor em carcinoma ex-adenoma pleomorfo
by: Mariano, Fernanda Viviane, 1984-
Published: (2009)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
by: I.P.C. Buzatto, et al.

Expressions of Bcl-2, Bax and Ki67 in the primary pterygium
by: Juan Li, et al.
Published: (2018-05-01)

Aromatase inhibitors in the treatment of endometriosis
by: Radosław Słopień, et al.
Published: (2016-03-01)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
by: Phung HT, et al.
Published: (2020-10-01)

Hubungan Ekspresi Ki-67 dengan Grading Histopatologi Liposarkoma
by: Afiati, et al.
Published: (2013-09-01)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
by: Tara Hyder, et al.
Published: (2021-07-01)

Neoplasias astrocitárias e correlação com as proteínas p53 mutada e Ki-67 Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins
by: Gustavo Rassier Isolan, et al.
Published: (2005-12-01)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
by: Zhou Qiong, et al.
Published: (2020-07-01)

DIFFICULTIES OF DIFFERENTIAL DIAGNOSIS BETWEEN ATYPICAL LEIOMYOMA AND LEIOMYOSARCOMA OF THE UTERINE BODY
by: E A Kogan, et al.
Published: (2016-03-01)

Clinicopathologic study and Ki-67 proliferative marker evaluation in human osteosarcomas Estudo clinicopatológico com avaliação do índice de proliferação celular avaliado pelo Ki-67 em osteossarcomas humanos
by: Larissa Cardoso Marinho, et al.
Published: (2005-12-01)

"EVALUATION OF THE EFFECTS OF BIOLOGICAL PROGNOSTIC AND PREDICTIVE FACTORS ON SURVIVAL OF BREAST CANCER PATIENTS "
by: F. Ensani, et al.
Published: (2007-04-01)

"EVALUATION OF THE EFFECTS OF BIOLOGICAL PROGNOSTIC AND PREDICTIVE FACTORS ON SURVIVAL OF BREAST CANCER PATIENTS "
by: F. Ensani, et al.
Published: (2007-06-01)

CD44 Expression in Meningioma and its Correlation with Proliferation Indices
by: Rasha Ramadan Mostafa, et al.
Published: (2017-08-01)

Immunoexpression of Ki-67 and endoglin corroborating hamartomatous nature of sialoangiolipoma
by: Swagatika Panda, et al.
Published: (2017-01-01)

Immunohistochemical consistency between primary tumors and lymph node metastases of gastric neuroendocrine carcinoma
by: Uchiyama Chieko, et al.
Published: (2012-06-01)

A cytohistological study of Ki-67 expression in ovarian tumors
by: Monisha Choudhury, et al.
Published: (2011-01-01)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
by: Nadine Norton, et al.
Published: (2018-06-01)

Role of Ki-67 in the Grading of Mucoepidermoid Carcinomas
by: Sobia Siddique
Published: (2015-06-01)

The characteristics of expression proliferation markers in endometrial hyperplasia
by: M R Dumanovskaya, et al.
Published: (2013-04-01)

Immunohistochemical Study of Tumor Cells Proliferative Activity at Different Graduations of Prostate Cancer
by: G. Y. Kudryavtsev, et al.
Published: (2019-12-01)

Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review
by: Tiziana Feola, et al.
Published: (2021-03-01)

Understanding Aromatase: A Mechanistic Basis for Drug Interactions and New Inhibitors
by: Lu, Wenjie
Published: (2012)

Synthesis and evaluation of potential aromatase inhibitors
by: Nazareth, W. M. A.
Published: (1988)

Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
by: Che YQ, et al.
Published: (2020-09-01)

Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target
by: Jessica Caciolla, et al.
Published: (2020-11-01)

Origin of aromatase inhibitory activity via proteochemometric modeling
by: Saw Simeon, et al.
Published: (2016-05-01)

Aromatase inhibitors in male sex
by: Santosh Kumar Singh
Published: (2013-01-01)

Immunohistochemical study of P53 protein expression in different prostate cancer Gleason grading groups
by: G. Y. Kudryavtsev, et al.
Published: (2020-12-01)

Cannot write session to /tmp/vufind_sessions/sess_ke0g5vica3m2057c8fn96e0t7t